Copyright © 2001 by the European Society of Cardiology.
Hotline Editorials
ESPRIT in context: pharmacology matters!
a Duke Clinical Research Institute, Durham, NC, U.S.A.
b Schering-Plough Research Institute, Kenilworth, NJ, U.S.A.
c COR Therapeutics, South San Francisco, CA, U.S.A.
References
- N Engl J Med. 1994;330:956961
[Abstract/Free Full Text] - N Engl J Med. 1997;336:16891696
[Abstract/Free Full Text] - Lancet. 1997;349:14291435[CrossRef][Web of Science][Medline]
- Lancet. 1997;349:14221428[CrossRef][Web of Science][Medline]
- Circulation. 1997;96:14451453
[Abstract/Free Full Text] - N Engl J Med. 1998;339:436443
[Abstract/Free Full Text] - N Engl J Med. 1998;338:14981505
[Abstract/Free Full Text] - Kong DF, Califf RM, Miller DP. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:28292835
[Abstract/Free Full Text] - Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998;98:26292635
[Free Full Text] - Lancet. 2000;356:20372044[CrossRef][Web of Science][Medline]
- Phillips DR, Teng W, Arfsten A. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:14881494
[Abstract/Free Full Text] - Tcheng JE, Ellis SG, George BS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:17571764
[Abstract/Free Full Text] - Tcheng J, Thel M, Jennings L, Joseph D, Card T, Talley J. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose IntegrilinTM in coronary intervention. Results of the PRIDE study. Eur Heart J. 1997;18:P3615
- Gibson C, Cohen D, Cohen E. Eptifibatide improves coronary flow reserve following stent placement: an ESPRIT substudy. Circulation. 2000;102:II-366
- O'Shea J, Cohen E, Buller C. Predictors of improvement in clinical outcomes of non-acute coronary stenting in the ESPRIT trial. Circulation. 2000;102:II-665
This article has been cited by other articles:
![]() |
A. Colombo and G. Stankovic The Value of Selectivity J. Am. Coll. Cardiol., February 21, 2006; 47(4): 719 - 720. [Full Text] [PDF] |
||||
![]() |
U. Zeymer, R. Zahn, R. Schiele, W. Jansen, E. Girth, A. Gitt, K. Seidl, R. Schroder, S. Schneider, and J. Senges Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial Eur. Heart J., October 1, 2005; 26(19): 1971 - 1977. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

